Urolog. pro Praxi, 2001; 3: 93-100

Léčba pokročilého a generalizovaného karcinomu prostaty

MUDr. Vít Vachalovský
Urologická klinika 1. LF UK a VFN Praha

Keywords: Prostate cancer, Androgen deprivation, Complete androgene blockade, Adverse side-effects.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachalovský V. Léčba pokročilého a generalizovaného karcinomu prostaty. Urol. praxi. 2001;2(3):93-100.

Prostata roste a funguje v multihormonálním prostředí, které je tvořeno androgeny, estrogeny, gonadotropiny, gonadotropin-releasing hormony a gestageny. V přehledu uvádím možné způsoby léčby pokročilého a generalizovaného karcinomu prostaty s ohledem na časování léčby a vedlejší nežádoucí účinky.

The treatment of advanced and metastatic prostate cancer

The prostate grows and functions withing a multihormonal environment. It consists of androgens, oestrogens, gonadotrophins, gonadotrophin-releasing hormones and gestagens. I show all possibilities of treatment of advanced and metastatic prostate cancer.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maatman T.J., Gupta M.K., Montie J.E.: Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J. Urol., 133, 4, 1985, 620-621. Go to original source... Go to PubMed...
    2. Sanford E. J., Drago J. R., Rohner T. J. Jr., Santen R., Lipton A.: Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J. Urol., 115, 1976, 2, 170-174. Go to original source... Go to PubMed...
    3. Baba S., Murai M., Jitsukawa S., Hata M., Tazaki H.: Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men. J. Urol., 119, 1978, 3, 375-380. Go to original source... Go to PubMed...
    4. Walsh P. C., Siiteri P. K.: Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J. Urol., 114, 1975, 2, 254-256. Go to original source... Go to PubMed...
    5. Trachtenberg J., Pont A.: Ketoconazole therapy for advanced prostate cancer. Lancet, II, 1984, 8400, 433. Go to original source... Go to PubMed...
    6. Vanuytsel L., Ang K. K., Vantongelen K., Drochmans A., Baert L., Schueren E.: Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J. Urol., 137, 1987, 5, 905-908. Go to original source... Go to PubMed...
    7. Byar D. P., Corle D. K.: Hormone therapy for prostate cancer results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monograph, 7, 1988, 165-170.
    8. Scher H. L., Cordon-Cordo C.: Current and future therapeutic strategies in metastatic hormonal-resistant prostate cancer. Problems Urol., 7, 1993, 226.
    9. Benson R. C., Wear J. B., Gill G. M.: Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J. Urol., 121, 1979, 4, 452-454. Go to original source... Go to PubMed...
    10. Mittelman A., Shukla S. K., Murphy G. P.: Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J. Urol., 115, 1976, 4, 409-412. Go to original source... Go to PubMed...
    11. Koutsilieris M., Tolis G.: Long term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. Prostate, 7, 1985, 1, 31-39. Go to original source... Go to PubMed...
    12. Chodak G. W.: Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. Urology, 33, 1989, 5, suppl. 1, 42-44. Go to original source... Go to PubMed...
    13. Peeling W. B.: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, 33, 1989, 5, suppl. 1, 1989, 45-52. Go to original source... Go to PubMed...
    14. Sufrin G., Coffey D. S.: Flutamide: mechanism of action of a new nonsteroidal antiandrogen. Invest. Urol., 13, 1976, 6, 429-434. Go to PubMed...
    15. Janknegt R. A., Abbou C. C., Bartoletti R., Bernstein-Hahn L., Bracken B. a ost.: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol., 149, 1993, 1, 77-83. Go to original source... Go to PubMed...
    16. Eisenberger M. A., Blumenstein B. A., Crawford E. D. a ost.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med., 339, 1998, 1036-1042. Go to original source... Go to PubMed...
    17. Prostate Cancer Trialists Collaborative Group (PCTCG): Maximum androgen blockade in advanced prostate cancer: a metaanalysis of 22 randomised trials. Eur. Urol. Update Series, 4, 1995, 186-194.
    18. Schroeder F.H.: Endocrine treatment of prostate cancer-recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. Brit. J. Urol., 83, 1999, 161-170. Go to original source... Go to PubMed...
    19. Bruchovsky N., Goldenberg S. L., Gleave M. E., Akakura K., Sato N., Rennie P.S.: Intermittent androgen blockade. In: Abrahamsson P.: Sborník přednášek, ,International conference on prostatic carcinoma, Copenhagen, 1995, 43-46.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.